Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

75.78 +0.60 (+0.80%)

Streaming Delayed Price Updated: 12:49 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗

May 05, 2026

Cytokinetics (CYTK) Q1 2026 Earnings Transcript

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

May 05, 2026

Via Chartmill

Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗

April 23, 2026

Via Chartmill

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗

February 24, 2026

Via Chartmill

CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗

February 14, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗

March 09, 2026

This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical development.

Via The Motley Fool

Topics Regulatory Compliance

Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗

February 24, 2026

Cytokinetics (CYTK) Q4 2025 Earnings Transcript

Via The Motley Fool

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for...

Via MarketMinute

Topics Intellectual Property

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Cytokinetics, Inc. (Nasdaq: CYTK) has officially cleared its final major regulatory hurdle for its flagship heart failure drug, MYQORZO (aficamten), receiving marketing authorization from the European...

Via MarketMinute

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...

Via MarketMinute

Topics Artificial Intelligence Economy

The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026

January 02, 2026

The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗

December 19, 2025

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Via Stocktwits

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? ↗

December 19, 2025

B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November.

Via The Motley Fool

Topics Regulatory Compliance

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

What Does the Market Think About Cytokinetics Inc? ↗

November 18, 2025

Via Benzinga

Cytokinetics (CYTK) Q3 2025 Earnings Transcript ↗

November 05, 2025

Cytokinetics (CYTK) Q3 2025 Earnings Transcript

Via The Motley Fool

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 01, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗

September 02, 2025

Via Benzinga

Topics Stocks

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

Headline News about Cytokinetics, Incorporated - Common Stock

Starting at $3.75/week.

Subscribe Today